A tirzepatide injection site reaction is usually a small patch of redness, itching, soreness, bruising, or rash where the needle went in. A raised spot or small lump can happen too. In the current Zepbound label, these reactions affected 6% to 8% of adults taking tirzepatide, compared with 2% taking placebo, an inactive comparison injection.
That is different from a serious allergic reaction. Swelling of the face or throat, trouble breathing or swallowing, fainting, a very fast heartbeat, or a severe widespread rash needs urgent medical attention under the label's warning. The location alone does not decide which kind of reaction it is; the symptoms and whether they stay local matter.
Tirzepatide injection site reaction rates in the label
The current Zepbound prescribing information, revised in August 2026, pools two weight-reduction trials. One was SURMOUNT-1, a 72-week trial of 2,539 adults. The label counts several local symptoms together rather than treating each as a separate side effect.
| Trial group | Adults with an injection-site reaction | Plain-language view |
|---|---|---|
| Placebo | 2% | About 1 in 50 |
| Zepbound 5 mg | 6% | About 1 in 17 |
| Zepbound 10 mg | 8% | About 1 in 13 |
| Zepbound 15 mg | 8% | About 1 in 13 |
The grouped term covers bruising, erythema (redness), pruritus (itching), pain, rash, and a general injection-site reaction. It does not mean every reaction had all of those features.
As of September 18, 2026, the day this article was written, the newest directly relevant publication we found was a case report published July 27, 2026. One man had immediate superficial wheals, or raised welts, with mild local redness, swelling, and itching when several injections apparently entered the skin rather than the fatty layer beneath it. No further severe whole-body episodes occurred after a clinician corrected the technique. One case cannot estimate risk or explain every local spot, but it reinforces using the instructions for the exact device supplied.
What it can look like and how long it lasts
A local reaction stays centered where the injection entered. It may look like a red patch, an itchy welt, a bruise, a tender spot, or a small raised area. A lasting lump, spreading warmth, drainage, or pain that keeps worsening is not something the trials define as a routine reaction; it deserves clinical review.
The honest answer on duration is less tidy than many online summaries suggest. The FDA's original Zepbound clinical review says 71.8% of recorded reactions began more than six hours after the shot, and 38.5% began between 24 hours and 14 days later. It does not publish a reliable typical number of days that a reaction lasted.
A pooled analysis of seven late-stage tirzepatide trials followed 5,025 treated adults with type 2 diabetes. It found that the majority of injection-site reactions first appeared within the first 16 weeks and resolved regardless of antidrug antibody status. Antidrug antibodies are immune proteins the body can make after encountering a medicine. All recorded local reactions in that analysis were nonserious and nonsevere, although four people stopped treatment because of them.
So a short-lived local patch fits the trial picture, but the research does not support promising that every reaction will clear in two or three days.
A local reaction is not the same as a serious allergy
Hypersensitivity means an allergic-type immune reaction. Angioedema is deeper swelling, often around the face, lips, tongue, or throat. These are not simply larger versions of an itchy spot at the needle site.
| More consistent with a local reaction | The label's serious-allergy warning |
|---|---|
| Redness, itching, bruising, soreness, or a small raised spot at the injection point | Face, lip, tongue, or throat swelling |
| Symptoms remain limited to that patch | Trouble breathing or swallowing |
| No faintness or whole-body symptoms | Severe rash or itching, fainting, dizziness, or a very rapid heartbeat |
The current label reports severe hypersensitivity in 0.1% of Zepbound-treated adults in two pooled weight-reduction studies and none in the placebo group. The Medication Guide tells patients to stop Zepbound and get medical help right away when the serious-allergy symptoms above occur. For a reaction that is hard to classify, the prescriber has more useful context than an image search. The broader tirzepatide side-effects guide covers the non-skin warnings without turning this page into a general list.
What the label says about site rotation
The Zepbound Instructions for Use tell patients to change the exact injection point each week. The same broad body area may be used again, but the point within it changes. The instructions also exclude skin that is tender, bruised, scaly, hard, scarred, damaged, pitted, thickened, or lumpy.
Rotation reduces repeated trauma to one patch of tissue; it does not guarantee that a local reaction will never happen. Where to inject tirzepatide covers the labeled body areas and why product-specific diagrams matter.
Compounded vials and brand pens are different devices
Promise's tirzepatide product page describes an injectable vial used under the skin and compounded with vitamin B12. Zepbound is available in branded pens and vials with its own Instructions for Use. Both involve the tirzepatide molecule, but the container, formulation, concentration, supplied equipment, and handling directions are not automatically interchangeable.
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. The prescriber's directions and the dispensing pharmacy's instructions control for the actual vial supplied.
A new or worsening local reaction is useful information for both the prescriber and pharmacy because they can identify the formulation, equipment, and lot involved. How to report peptide side effects explains what details make that report useful.
Would changing medicines solve the reaction?
Not necessarily. Semaglutide is a different molecule with different product presentations and its own side-effect data. A local reaction to tirzepatide does not prove the same thing will happen with semaglutide, and the reverse is also true. Comparing the two is a prescriber decision, not a device swap.
What helps a prescriber judge the reaction
The most useful description is concrete: when the mark appeared, whether it spread, how long it lasted, what it looked and felt like, which body area was used, and whether breathing trouble, facial swelling, faintness, fever, drainage, or whole-body symptoms occurred. A photograph and the pharmacy label can preserve details that fade before a visit.
At Promise, a licensed provider reviews every request, and not everyone qualifies. That same clinical relationship is where a new reaction can be assessed against the prescription and health history rather than guessed at from a picture.